Affimed's CEO named one of the Top 25 biotech CEOs of 2021.


The Healthcare Technology Report recognizes leaders who have stood out for their continued dedication to patient care and significant contributions to the advancement of medicine.



The Healthcare Technology Report is pleased to announce The Top 25 Biotech CEOs of 2021. The past twelve months, more than any other period in recent history, have showcased the outstanding talent, ingenuity, and determination of the world’s leading biotechnology executives and their organizations. Responding proactively to the day’s most pressing needs, these CEOs lean in, take on daunting risks head-on and boldly charge forth for the benefit of healing not only the vulnerable segments of our population but in some cases humanity at large.


In the areas of vaccine development, oncology, regenerative medicine, vascular disease, autoimmune disease, pain management, neurodegenerative disease, ophthalmology, and other areas, these CEOs have successfully advanced research and brought breakthrough drugs and treatments to market, some after long periods of challenging research and development and others in record-breaking time. Notably, many of the awardees have also successfully guided their companies through rapid organizational and financial growth.


Each of this year’s honorees has made remarkable strides for the biotechnology industry, from leading the quest to develop vaccines for the novel coronavirus to changing the way the industry develops and tests new treatments. From hundreds of nominees, these executives have stood out for their continued dedication to patient care, and for their significant contributions to the advancement of medicine. Please join us in recognizing the accomplishments of The Top 25 Biotech CEOs of 2021.


Original news